



# STATE OF IOWA

CHESTER J. CULVER, GOVERNOR  
PATTY JUDGE, LT. GOVERNOR

DEPARTMENT OF HUMAN SERVICES  
CHARLES J. KROGMEIER, DIRECTOR

## Iowa Medicaid Drug Utilization Review (DUR) Commission Meeting March 3, 2010

**Location: Learning Resource Center  
3550 Mills Civic Parkway  
West Des Moines, Iowa**

**Time: 9:30 a.m. – 1:30 p.m.**

### Final Agenda

1. Welcome & Introductions
  - a) Commission Members and Staff
  - b) Approval of the minutes
2. Iowa Medicaid Enterprise Update(s)
3. Case Studies
4. Public Comment (See Conflict of Interest Disclosure Form)
5. Prior Authorization
  - a) Duloxetine (*Cymbalta*), Pregabalin (*Lyrica*), Milnacipran (*Savella*) – Second Review
  - b) Extended Release Guanfacine (*Intuniv*) – Initial Review
6. Public Comment (See Conflict of Interest Disclosure Form)
7. Focus Studies/Provider Education Initiatives
  - a) ACE Inhibitors Combined with Angiotensin Receptor Blockers – Follow Up
  - b) Utilization Patterns of Cholesterol Lowering Medication Pre- and Post-MI – Second Data Set
  - c) Proton Pump Inhibitors Plus Clopidogrel (*Plavix*) – Second Review
  - d) Atypical Antipsychotics Plus Anticholinergics – Initial Review
  - e) Antipsychotic Utilization in Children & Adolescents 2005 vs. 2009 – Initial Review
  - f) Duplicate Antihistamines – Initial Review
8. Miscellaneous
  - a) DUR Digest
  - b) SMAC Update
  - c) MedWatch

9. Executive Closed Session
  - a) Approval of Minutes
  - b) Member Profiles
12. Adjournment

Individuals attending meetings of the DUR Commission shall have an opportunity to address the Commission. This opportunity will be granted twice during the open portion of the meeting. In order to accommodate all interested parties, all speakers are requested to limit their comments to **5 minutes or less**. If you represent a drug manufacturer as an employee, as a contractor, as a member of the manufacturer's Speaker Bureau, or by any other means, we expect you to cover your individual product or entire product line in that five-minute time frame. Speakers who represent multiple manufacturers will share their 5 minutes with the other manufacturer representative(s) whose product they are speaking on.

**[www.iadur.org](http://www.iadur.org)**

For more information contact the DUR Project Coordinator, Pam Smith, R.Ph., at [info@iadur.org](mailto:info@iadur.org) or (515) 974-3131